Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InhaleRx Limited ( (AU:IRX) ) has provided an announcement.
InhaleRx Limited reported its quarterly cash flow for the period ended 31 December 2025, showing net operating cash outflows of A$628,000 for the quarter and A$899,000 year-to-date, largely driven by research and development and administrative expenses, partly offset by government grants and tax incentives. The company recorded no investing cash flows during the period, but strengthened its cash position through A$535,000 in equity issuance and A$774,000 in new borrowings (partly offset by repayments and transaction costs), resulting in net financing inflows of A$894,000 and an overall increase in cash and cash equivalents of A$170,000 for the quarter, indicating continued reliance on external funding to support its operations.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
More about InhaleRx Limited
InhaleRx Limited is an Australian-listed company that appears to operate in a research and development-intensive segment, with significant expenditure directed toward R&D and limited receipts from customers, suggesting an early-stage or pre-commercial focus within the healthcare or pharmaceutical technology sector.
Average Trading Volume: 271,657
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.16M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.